NCT03807843View on ClinicalTrials.gov

Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006)

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

July 16, 2019

Primary Completion Date

May 13, 2021

Study Completion Date

May 13, 2021

Conditions
Chikungunya Virus Infection
Interventions
BIOLOGICAL

V184

Recombinant live Schwarz-strain measles-vectored vaccine expressing chikungunya virus structural proteins. Liquid frozen, life attenuated, measles vectored V184 vaccine administered via IM injection at 5 × 10\^5 TCID50 (+/- 0.5 log) per dose.

OTHER

Placebo

Sterile physiological saline for IM injection

Trial Locations (1)

00935

San Juan Hospital, Research Unit, San Juan

All Listed Sponsors
collaborator

Walter Reed Army Institute of Research (WRAIR)

FED

lead

Themis Bioscience GmbH

INDUSTRY

NCT03807843 - Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006) | Biotech Hunter | Biotech Hunter